IGF1 and acromegaly: The GH receptor antagonist pegvisomant (PEG), approved by the FDA in 2003 and the EMA in 2004 for the treatment of acromegaly, can normalize IGF-I concentrations in roughly 60–97% of patients [23,24]; however, it does not reduce GH concentrations or tumor volume.